Please login to the form below

Not currently logged in
Email:
Password:

patisiran

This page shows the latest patisiran news and features for those working in and with pharma, biotech and healthcare.

The year of the blockbuster

The year of the blockbuster

Patisiran from Alnylam and Sanofi: Patisiran is an intravenously administered RNAi therapeutic targeting the transthyretin gene for the treatment of patients with debilitating hereditary transthyretin-mediated amyloidosis. ... The FDA granted patisiran

Latest news

  • Pfizer drug gets speedy FDA review for rare heart failure complication Pfizer drug gets speedy FDA review for rare heart failure complication

    There is potential competition in the offing however from Alnylam's Sanofi-partnered patisiran, because while that company is focused more on polyneuropathy than cardiomyopathy in its clinical trials, it has ... Added to that, Pfizer’s drug can be

  • FDA lifts clinical hold on Sanofi’s haemophilia drug FDA lifts clinical hold on Sanofi’s haemophilia drug

    The company recently abandoned one of its gene-silencing drugs – revusiran for the rare disease hereditary ATTR amyloidosis with cardiomyopathy – although its new lead program patisiran for ATTR plus polyneuropathy remains ... Patisiran – also

  • Alnylam takes off on APOLLO trial results Alnylam takes off on APOLLO trial results

    APOLLO showed that Alnylam's lead RNAi therapy patisiran is effective as a treatment for the rare disorder hereditary ATTR amyloidosis with polyneuropathy , and critically was well-tolerated by patients, sparking ... Patisiran also improved secondary

  • Ionis says rare disease drug works, but safety concerns linger Ionis says rare disease drug works, but safety concerns linger

    Investors were spooked by the risks and Ionis shares declined 11%, while rival Alnylam - which is expecting phase III results for its FAP therapy patisiran in the coming months - rose 13%. ... Alnylam dropped lead amyloidosis drug revusiran last year

  • Alnylam pulls lead drug revusiran after deaths in phase III trial Alnylam pulls lead drug revusiran after deaths in phase III trial

    Shares in the company fell more than 40% yesterday as news of the setback emerged, and Alnylam will now have to concentrate its efforts on patisiran, another RNAi drug in phase ... On a conference call, Alnylam's chief medical officer Akshay Vaishnaw

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The original deal was forged back in 2012 when Genzyme gained access to patisiran for the treatment of transthyretin familial amyloid polyneuropathy in Japan and other Asian markets.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics